AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank83
5Y CAGR-17.0%
Studio
Year-over-Year Change

Year-over-year operating income growth rate

5Y CAGR
-17.0%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
4 yr
Consecutive growthAccelerating
PeriodValue
202530.14%
202421.66%
2023-64.77%
2022-95.89%
2021-196.18%
202076.55%
20190.00%